Phospho-RPS6KB1 (Ser424) Antibody

What is RPS6KB1 and what role does phosphorylation at Ser424 play?

RPS6KB1 (Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 1), also known as S6K1, is a serine/threonine kinase that phosphorylates ribosomal protein S6, playing a crucial role in protein translation, cell size regulation, and energy metabolism. Phosphorylation of RPS6KB1 at Ser424 is particularly significant because it contributes to the substrate specificity of the kinase. When Ser424 is phosphorylated, particularly in combination with Ser429, it enables RPS6KB1 to recognize and phosphorylate specific substrates beyond its canonical targets. This phosphorylation is typically mediated by Cyclin-dependent kinase 5 (Cdk5) and works in conjunction with other phosphorylation sites to create what researchers call a "kinase phospho-code" that integrates multiple signaling pathways .

What experimental approaches are recommended for detecting RPS6KB1 phosphorylation at Ser424?

Several methodological approaches are recommended for detecting Ser424 phosphorylation:

• Western Blotting (WB): Using phospho-specific antibodies that recognize RPS6KB1 phosphorylated at Ser424. This is the most commonly used method and provides quantifiable data .

• Immunohistochemistry (IHC): This approach allows visualization of phosphorylated RPS6KB1 in tissue sections, particularly useful for clinical samples and providing spatial information within tissues .

• Immunofluorescence (IF): Provides cellular localization information of phosphorylated RPS6KB1, allowing researchers to determine subcellular distribution .

• Proximity Ligation Assay (PLA): As described in developmental research, this method uses a dual recognition antibody pair set, with one antibody against the RPS6KB1 protein and another against the specific Ser424 phosphorylated site. Each dot in the assay represents a single phosphorylated protein, allowing for highly specific detection and quantification at the single-molecule level .

What controls should be included when studying RPS6KB1 Ser424 phosphorylation?

When studying RPS6KB1 Ser424 phosphorylation, researchers should include the following controls:

• Positive controls: Cell lines or tissues known to express phosphorylated RPS6KB1 at Ser424, such as insulin-stimulated adipocytes or IFN-γ-treated U937 monocytes as described in research studies .

• Negative controls: Samples treated with phosphatase to remove phosphorylation, or cells treated with specific kinase inhibitors that prevent phosphorylation at Ser424.

• Specificity controls: Using cells expressing wild-type RPS6KB1 versus RPS6KB1 with Ser424 mutated to alanine (non-phosphorylatable) to validate antibody specificity.

• Loading controls: For Western blotting, including antibodies against total RPS6KB1 to normalize phosphorylation signals and ensure equal protein loading.

• Treatment controls: Including samples treated with known inducers of S6K1 phosphorylation, such as insulin, to demonstrate dynamic changes in phosphorylation status.

How does phosphorylation at Ser424 affect RPS6KB1's substrate specificity?

Research has revealed that phosphorylation at Ser424, particularly when combined with phosphorylation at Ser429, creates a conformational switch in RPS6KB1 that significantly alters its substrate specificity. This multisite phosphorylation is essential for high-affinity binding and phosphorylation of specific targets that differ from canonical RPS6KB1 substrates .

Experimental evidence from studies using phospho-deficient and phospho-mimetic mutations demonstrates that:

• RPS6KB1 constructs bearing Ala mutations at either Ser424 or Ser429 show markedly reduced phosphorylation of EPRS (glutamyl-prolyl tRNA synthetase) at Ser999, but maintain normal phosphorylation of RPS6 at Ser235/236 .

• Phosphorylation of EPRS Ser999 was observed only when RPS6KB1 contained phospho-mimetic mutations at both Ser424 and Ser429, while RPS6 phosphorylation remained independent of these C-terminal domain phospho-mimetic mutations .

This substrate-switching mechanism represents a sophisticated regulatory system that allows the kinase to selectively phosphorylate different substrates under different conditions or in response to different signals, integrating inputs from both mTORC1 and Cdk5 signaling pathways .

What is the relationship between mTORC1 signaling, Cdk5, and Ser424 phosphorylation?

The relationship between mTORC1 signaling, Cdk5, and Ser424 phosphorylation represents a complex integration of multiple signaling pathways:

• mTORC1 pathway: Canonically phosphorylates RPS6KB1 at Thr389, which is essential for basic kinase activation. This phosphorylation alone is sufficient for RPS6KB1 to phosphorylate its traditional substrate, ribosomal protein S6 .

• Cdk5 pathway: Phosphorylates RPS6KB1 at Ser424 and Ser429 in the C-terminal domain. Research demonstrates that Cdk5 immunoprecipitated from IFN-γ-treated U937 cells directly phosphorylates these sites on RPS6KB1 .

• Integration: Full activation of RPS6KB1 for certain substrates requires both canonical phosphorylation at Thr389 by mTORC1 and phosphorylation at Ser424 and Ser429 by Cdk5. This integrated phosphorylation pattern creates what researchers term a "target-selective kinase phospho-code" .

• Functional consequences: This multisite phosphorylation directs RPS6KB1 to phosphorylate specific substrates involved in processes like insulin-stimulated adipocyte lipid metabolism, representing a higher-order regulatory mechanism that allows for conditional substrate targeting .

What novel substrates are regulated by RPS6KB1 phosphorylated at Ser424?

Unbiased proteomic analysis has identified several novel substrates that are specifically phosphorylated by RPS6KB1 when it is phosphorylated at both Thr389 and Ser424/Ser429:

• EPRS (glutamyl-prolyl tRNA synthetase): Phosphorylated at Ser999 specifically by multisite-phosphorylated RPS6KB1 .

• Coenzyme A synthase: Identified through proteomic analysis as a target of multisite-phosphorylated RPS6KB1 in insulin-stimulated adipocytes .

• Lipocalin 2: Another target identified in insulin-stimulated adipocytes .

• Cortactin: Also identified as a substrate in the adipocyte context .

These findings suggest that the phosphorylation of RPS6KB1 at Ser424 and Ser429, in addition to Thr389, creates a specific signaling node that directs the kinase to phosphorylate a subset of targets involved in specialized cellular processes, particularly those related to adipocyte lipid metabolism .

How does RPS6KB1 phosphorylation status relate to cancer prognosis?

Extensive meta-analysis research has established a significant correlation between RPS6KB1 phosphorylation and cancer outcomes:

What are the key technical considerations when using Phospho-RPS6KB1 (Ser424) antibodies?

When working with Phospho-RPS6KB1 (Ser424) antibodies, researchers should consider several technical factors:

• Antibody specificity: Ensure the antibody specifically recognizes RPS6KB1 phosphorylated at Ser424 and not other phosphorylation sites. Some commercially available antibodies may recognize multiple phosphorylation sites (e.g., pSer424, pThr421) . Verification through peptide competition assays or phospho-deficient mutants is recommended.

• Species cross-reactivity: Verify that the antibody reacts with your species of interest. Based on commercial antibody information, many Phospho-RPS6KB1 (Ser424) antibodies react with human, mouse, and rat samples .

• Application compatibility: Confirm that the antibody is validated for your specific application (WB, IHC, IF, etc.). Different antibodies may perform differently across various techniques .

• Sample preparation: Phosphorylation states can be labile; include phosphatase inhibitors in all lysis buffers and maintain samples at cold temperatures during processing to preserve phosphorylation status.

• Signal amplification: For techniques like IHC where signal may be limiting, consider using signal amplification methods like tyramide signal amplification or polymer-based detection systems.

• Quantification approaches: For Western blotting, normalize phospho-specific signals to total RPS6KB1 levels to account for expression differences between samples.

How can researchers experimentally validate the specificity of Phospho-RPS6KB1 (Ser424) antibodies?

A rigorous experimental validation approach for Phospho-RPS6KB1 (Ser424) antibodies should include:

• Phospho-deficient mutants: Express wild-type RPS6KB1 versus RPS6KB1 with Ser424 mutated to alanine (non-phosphorylatable) and compare antibody reactivity. A truly specific antibody will not detect the S424A mutant.

• Phosphatase treatment: Treat lysates with lambda phosphatase to remove phosphorylation and confirm loss of antibody signal while total RPS6KB1 signal remains unchanged.

• Peptide competition: Pre-incubate the antibody with phosphorylated and non-phosphorylated peptides containing the Ser424 site. A specific signal should be blocked only by the phosphorylated peptide.

• Induction experiments: Treat cells with agents known to induce Ser424 phosphorylation (e.g., insulin) and confirm increased antibody signal.

• Inhibition experiments: Pre-treat cells with Cdk5 inhibitors before stimulation to prevent Ser424 phosphorylation and confirm reduced antibody signal.

• Kinase assays: Perform in vitro kinase assays with recombinant Cdk5/p35 and RPS6KB1, and verify that the antibody detects the resulting phosphorylation.

How can multisite phosphorylation of RPS6KB1 be studied experimentally?

Studying the complex multisite phosphorylation of RPS6KB1 requires sophisticated experimental approaches:

• Site-directed mutagenesis: Creating single and combination phospho-deficient (Ser/Thr to Ala) or phospho-mimetic (Ser/Thr to Asp/Glu) mutations at multiple phosphorylation sites (e.g., Thr389, Ser424, Ser429) to study their functional significance individually and in combination .

• Phospho-specific antibodies: Using antibodies that recognize specific individual phosphorylation sites to monitor phosphorylation status at multiple sites simultaneously .

• Mass spectrometry: Performing phospho-proteomic analysis to identify all phosphorylation sites on RPS6KB1 and quantify their relative abundance under different conditions.

• Kinase inhibitors: Using specific inhibitors of mTORC1 (e.g., rapamycin) and Cdk5 to block phosphorylation at certain sites and observe the effects on substrate phosphorylation .

• In vitro kinase assays: Using purified kinases (mTORC1, Cdk5/p35) to phosphorylate recombinant RPS6KB1 in vitro and analyze the phosphorylation sites and their effects on kinase activity and substrate specificity .

• Substrate phosphorylation assays: Measuring phosphorylation of downstream substrates (e.g., EPRS at Ser999 or RPS6 at Ser235/236) to assess the functional consequences of RPS6KB1 phosphorylation at different sites .

• Structural studies: Using techniques like hydrogen-deuterium exchange mass spectrometry or X-ray crystallography to understand how multisite phosphorylation induces conformational changes in RPS6KB1.

How can researchers address inconsistent detection of Phospho-RPS6KB1 (Ser424) in experimental samples?

When facing inconsistent detection of Phospho-RPS6KB1 (Ser424), researchers should consider these methodological solutions:

• Sample preservation: Phosphorylation can be rapidly lost during sample preparation. Always include comprehensive phosphatase inhibitor cocktails in lysis buffers and keep samples cold throughout processing.

• Rapid fixation: For tissue samples, ensure rapid fixation to preserve phosphorylation status. Consider using phospho-specific fixatives like those containing phosphatase inhibitors.

• Stimulation conditions: Optimize stimulation conditions (timing, concentration) for inducers like insulin or serum that promote Ser424 phosphorylation.

• Antibody validation: Verify antibody performance using positive control lysates from cells known to have high levels of Ser424 phosphorylation.

• Signal enhancement: For weak signals, consider using signal amplification methods or more sensitive detection systems.

• Normalization approach: For quantitative comparisons, normalize phospho-signals to total RPS6KB1 rather than housekeeping genes to account for expression level differences.

• Cross-reactivity: Test for potential cross-reactivity with other phosphorylated proteins or with other phosphorylation sites on RPS6KB1 itself.

What are the current research frontiers regarding RPS6KB1 Ser424 phosphorylation?

Current research frontiers in RPS6KB1 Ser424 phosphorylation include:

• Substrate networks: Further identifying and characterizing the complete set of substrates specifically regulated by multisite phosphorylated RPS6KB1 (including Ser424) in different cellular contexts .

• Structural basis: Elucidating the structural changes induced by phosphorylation at Ser424 and how these alterations affect substrate recognition.

• Cancer therapeutics: Developing strategies to target the specific functions of RPS6KB1 that are dependent on Ser424 phosphorylation in cancer, given its association with poor prognosis .

• Integration with other signaling pathways: Understanding how the Cdk5-RPS6KB1 axis intersects with other signaling networks beyond mTORC1, particularly in specific disease contexts.

• Tissue-specific roles: Characterizing the tissue-specific functions of Ser424 phosphorylation, as recent research suggests differential roles in different cancer types .

• Dynamic regulation: Developing methods to monitor real-time changes in Ser424 phosphorylation in living cells to understand its temporal dynamics in response to various stimuli.